Syros Pharmaceuticals

About:

Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits.

Website: http://syros.com

Twitter/X: SyrosPharma

Top Investors: Blue Owl, OrbiMed, ARCH Venture Partners, Fidelity, Deerfield

Description:

Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D. Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.

Total Funding Amount:

$620M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Watertown, Massachusetts, United States

Founded Date:

2012-01-01

Contact Email:

Infor(AT)syros.com

Founders:

Alex Rives, Jay Bradner, Nathanael Gray, Richard Young, Richard Young

Number of Employees:

101-250

Last Funding Date:

2023-12-19

IPO Status:

Public

© 2025 bioDAO.ai